Advanced

Intermittent androgen deprivation therapy in patients with prostate cancer : Connecting the dots

Abrahamsson, Per Anders LU (2017) In Asian Journal of Urology 4(4). p.208-222
Abstract

Intermittent androgen deprivation therapy (IADT) is now being increasingly opted by the treating physicians and patients with prostate cancer. The most common reason driving this is the availability of an off-treatment period to the patients that provides some relief from treatment-related side-effects, and reduced treatment costs. IADT may also delay the progression to castration-resistant prostate cancer. However, the use of IADT in the setting of prostate cancer has not been strongly substantiated by data from clinical trials. Multiple factors seem to contribute towards this inadequacy of supportive data for the use of IADT in patients with prostate cancer, e.g., population characteristics (both demographic and clinical), study... (More)

Intermittent androgen deprivation therapy (IADT) is now being increasingly opted by the treating physicians and patients with prostate cancer. The most common reason driving this is the availability of an off-treatment period to the patients that provides some relief from treatment-related side-effects, and reduced treatment costs. IADT may also delay the progression to castration-resistant prostate cancer. However, the use of IADT in the setting of prostate cancer has not been strongly substantiated by data from clinical trials. Multiple factors seem to contribute towards this inadequacy of supportive data for the use of IADT in patients with prostate cancer, e.g., population characteristics (both demographic and clinical), study design, treatment regimen, on- and off-treatment criteria, duration of active treatment, endpoints, and analysis. The present review article focuses on seven clinical trials that evaluated the efficacy of IADT vs. continuous androgen deprivation therapy for the treatment of prostate cancer. The results from these clinical trials have been discussed in light of the factors that may impact the treatment outcomes, especially the disease (tumor) burden. Based on evidence, potential candidate population for IADT has been suggested along with recommendations for the use of IADT in patients with prostate cancer.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Continuous androgen deprivation therapy, Intermittent androgen deprivation therapy, Prostate cancer, Study designs and outcomes, Tumor burden
in
Asian Journal of Urology
volume
4
issue
4
pages
208 - 222
external identifiers
  • scopus:85029502358
  • wos:000414501900003
DOI
10.1016/j.ajur.2017.04.001
language
English
LU publication?
yes
id
14cddabc-0fed-46ae-8c92-4958a0155597
date added to LUP
2017-10-10 15:27:31
date last changed
2018-01-16 13:22:45
@article{14cddabc-0fed-46ae-8c92-4958a0155597,
  abstract     = {<p>Intermittent androgen deprivation therapy (IADT) is now being increasingly opted by the treating physicians and patients with prostate cancer. The most common reason driving this is the availability of an off-treatment period to the patients that provides some relief from treatment-related side-effects, and reduced treatment costs. IADT may also delay the progression to castration-resistant prostate cancer. However, the use of IADT in the setting of prostate cancer has not been strongly substantiated by data from clinical trials. Multiple factors seem to contribute towards this inadequacy of supportive data for the use of IADT in patients with prostate cancer, e.g., population characteristics (both demographic and clinical), study design, treatment regimen, on- and off-treatment criteria, duration of active treatment, endpoints, and analysis. The present review article focuses on seven clinical trials that evaluated the efficacy of IADT vs. continuous androgen deprivation therapy for the treatment of prostate cancer. The results from these clinical trials have been discussed in light of the factors that may impact the treatment outcomes, especially the disease (tumor) burden. Based on evidence, potential candidate population for IADT has been suggested along with recommendations for the use of IADT in patients with prostate cancer.</p>},
  author       = {Abrahamsson, Per Anders},
  keyword      = {Continuous androgen deprivation therapy,Intermittent androgen deprivation therapy,Prostate cancer,Study designs and outcomes,Tumor burden},
  language     = {eng},
  number       = {4},
  pages        = {208--222},
  series       = {Asian Journal of Urology},
  title        = {Intermittent androgen deprivation therapy in patients with prostate cancer : Connecting the dots},
  url          = {http://dx.doi.org/10.1016/j.ajur.2017.04.001},
  volume       = {4},
  year         = {2017},
}